NCT03233204
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+, ATM, DNA damage repair mutations
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 12 Months to 21 Years (Child, Adult)
Location of Metastases:
Additional Notes: Patient must have enrolled on the Pediatric MATCH Screening Trial (NCT03155620)
Exclusions: Patients over the age of 21; Patients who have received prior exposure to PARP inhibitors (e.g. olaparib, veliparib, niraparib, rucaparib, talazoparib); Patients with symptomatic or uncontrolled central nervous system (CNS) metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03233204